Methods of treating cancer comprising targeting nqo1
AssigneeBoard of Regents, The University of Texas System
InventorDavid BOOTHMAN
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for determining whether an individual with cancer is suitable for a treatment with an NQO1 bioactivatable drug, predicting responsiveness of an individual with cancer to a treatment with an NQO1 bioactivatable drug, and treating an individual with cancer with an NQO1 bioactivatable drug composition.
Claims32
1:
- A method of determining whether an individual with cancer is suitable for a treatment with an NQO1 bioactivatable drug, comprising measuring the protein level of the NQO1 expression and the catalase expression in the cancer cells in the individual, wherein a ratio of the NQO1 level over the catalase level in the cancer cells from the individual being at least about 50-fold of the ratio of a normal tissue indicates that the individual is suitable for the treatment.
A method of predicting responsiveness of an individual with cancer to a treatment with an NQO1 bioactivatable drug, comprising measuring the protein level of the NQO1 expression and the catalase expression in the cancer cells in the individual, wherein a ratio of the NQO1 level over the catalase level in the cancer cells from the individual being at least about 50-fold of the ratio of a normal tissue indicates that the individual is more likely to be responsive to the treatment.
A method of treating an individual with cancer, comprising administering an effective amount of an NQO1 bioactivatable drug to the individual, wherein the individual is selected for the treatment if the ratio of the NQO1 level over the catalase level in the cancer cells from the individual is at least about 50-fold of the ratio in a normal tissue.
The method of claim 1, wherein the ratio of the NQO1 level over the catalase level in the cancer cells from the individual is at least about 60-fold or at least about 70-fold of the ratio in a normal tissue.
A method of determining whether an individual with cancer is suitable for a treatment with an NQO1 bioactivatable drug, comprising measuring the protein level of NQO1 expression in the cancer cells from the individual, wherein the NQO1 enzymatic activity being at least about 50 units in the cancer cells indicates that the individual is suitable for the treatment.
A method of predicting responsiveness of an individual with cancer to a treatment with an NQO1 bioactivatable drug, comprising measuring the protein level of NQO1 expression in the cancer cells from the individual, wherein the NQO1 enzymatic activity being at least about 50 units in the cancer cells indicates that the individual is more likely to be responsive to the treatment.
A method of treating an individual with cancer, comprising administering an effective amount of an NQO1 bioactivatable drug to the individual, wherein the individual is selected for the treatment if the NQO1 enzymatic activity in the cancer cells of the individual is at least about 50 units.
A method of determining whether an individual with cancer is suitable for a treatment with an NQO1 bioactivatable drug, comprising detecting an NQO1 gene polymorphism C465T mutation in a sample from the individual, wherein the presence of C465T/C465T polymorphism indicates that the individual is suitable for the treatment.
A method of predicting responsiveness of an individual with cancer to a treatment with an NQO1 bioactivatable drug, comprising detecting an NQO1 gene polymorphism C465T mutation in a sample from the individual, wherein the presence of C465T/C465T polymorphism indicates that the individual is likely to be responsive to the treatment.
A method of treating an individual with cancer, comprising administering an effective amount of an NQO1 bioactivatable drug to the individual, wherein the individual is selected for the treatment based on the presence of C465T/C465T polymorphism in a sample from the individual.
The method of claim 1, further comprising monitoring treatment of an NQO1 bioactivatable drug in an individual by measuring one or more protein levels in cancer cells from the individual before and after the treatment, wherein the protein measured is selected from the group consisting of NQO1, catalase, small μ-calpain subunit, large μ-calpain subunit, apoptosis inducing factor (AIF), and PARP-1.
The method of claim 1, wherein the NQO1 bioactivatable drug is a β-lapachone compound, streptonigrin, or deoxynyboquinone (DNQ).
The method of claim 1, wherein the cancer is lung cancer, prostate cancer, breast cancer, pancreatic cancer, colon cancer or melanoma.
The method of claim 1, wherein the protein level of the NQO1 expression and/or the catalase expression is measured by the enzymatic activity or the amount of the protein in the cancer cells and in the normal tissue from the individual.
The method of claim 1, wherein the individual is a human.
The method of claim 1, wherein the normal tissue is an associated normal tissue.
The method of claim 1, wherein the cancer cells are from a cancer biopsy from the individual or circulating cancer cells from the individual.
A method for treating cancer in an individual in need thereof, comprising administering a DNA damaging therapy to an individual in need thereof and an NQO1 bioactivatable drug.
Dependencies are inferred from the claim text.